PMC6426481_01
Diagnostic and treatment delays in patients with breast cancer. Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016.
JGO.2016.009050f1.jpg
PMC6426481_01_JGO.2016.009050f1.jpg
F1
Survival probability of patients with breast cancer at 12 and 36 months, according to clinical stages. Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016.
JGO.2016.009050f2.jpg
PMC6426481_01_JGO.2016.009050f2.jpg
F2
A significant difference in survival was observed between the immunohistochemical profiles ER positive/PR positive/HER2 negative versus ER negative/PR negative/HER2 positive; P = .0179), between patients with axillary-negative versus axillary-positive nodes (P = .0054), and between grouped clinical stages (P = .0054; Fig 2).